DocWire News Editors

DocwireNews

High-dose inactivated influenza vaccine did not reduce all-cause death or hospitalization for cardiopulmonary causes compared with a standard-dose vaccine in patients with high-risk cardiovascular disease (CVD), according to data presented by Orly Vardeny, PharmD, MS, of associate professor at University of Minnesota Medical School, at a news briefing at the American Heart Association Scientific Sessions 2020.According to Dr. Vardeny, individuals with underlying CVD are more susceptible to influenza complications and adverse clinical outcomes. Observational studies have demonstrated a temporal association between influenza and acute cardiac events. In addition, a meta-analysis of randomized clinical trials showed that influenza vaccination was associated with lower risk of major adverse cardiovascular events compared with no vaccination.The high-dose vaccine contains four times the amount of antigen and has been shown to reduce risk for laboratory symptomatic influenza compared with the standard dose. However, the Advisory Committee on Immunization Practices does not preferentially recommend one vaccine formulation over another.Here, Dr. Vardeny and colleagues hypothesized that high-dose influenza vaccine would improve clinical outcomes in patients with CVD compared with standard dose.The INVESTED trial enrolled individuals within 12 months of hospitalization of myocardial infarction or 24 months of hospitalization for heart failure plus one of a multitude of additional risk factors. The patients were randomly assigned to high-dose trivalent inactivated influenza vaccine (n=2,630) or standard-dose quadrivalent inactivated influenza vaccine (n=2,630). Patients could be revaccinated with their vaccine type for up to three influenza seasons. The primary endpoint was composite of death or cardiopulmonary hospitalization within each influenza season.The study&rsquo;s Data Monitoring Committee recommended early termination of the trial for futility. There were no significant difference between groups with regard to all-cause mortality or cardiopulmonary hospitalization (HR=1.06; 95% CI, 0.97 to 1.17; P=0.21). Results were consistent across prespecified secondary endpoints and subgroups. In general, the influenza vaccine as very well tolerated. Patients who received high-dose vaccine had a higher frequency of injection site pain or swelling as well as myalgias.Dr. Vardeny said that it is important to place these results into context.&ldquo;We compared two active vaccine formulations in a very high-risk population and both of these are known to reduce influenza illness,&rdquo; she said. &ldquo;Thus receipt of any influenza vaccine in high-risk patients may be protective and limit potential benefit of high-dose vaccine in reducing cardiopulmonary events.&ldquo;Importantly these results do not detract from prior trials showing benefit of high-dose vaccine on reducing influenza illness nor do they minimize the importance of influenza vaccine in patients with high-risk cardiovascular disease for whom influenza vaccination remains strongly recommended,&rdquo; Dr. Vardeny concluded.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

High-Dose Influenza Vaccine Similar to Standard-Dose for All-Cause Death, Cardiopulmonary Events

AHA Scientific Sessions 2020

High-dose inactivated influenza vaccine did not reduce all-cause death or hospitalization for cardiopulmonary causes compared with a standard-dose vaccine in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe